Navigation Links
DOR BioPharma Announces NIH Grant Award to Support Phase 1/2 Clinical Trial of DOR201 in Radiation Enteritis
Date:9/8/2009

"anticipates," "believes," "intends," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. DOR cannot assure you that it will be able to successfully develop or commercialize products based on its technology, including DOR201, orBec(R) and LPM(TM), particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that its cash expenditures will not exceed projected levels, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect the future use of orBec(R) for gastrointestinal GVHD include the risks that: the FDA's requirement that DOR conduct additional clinical trials to demonstrate the safety and efficacy of orBec(R) will take a significant amount of time and money to complete and positive results leading to regulatory approval cannot be assumed; DOR is dependent on the expertise, effort, priorities and contract
'/>"/>
SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Research-Based Biopharmaceutical Company Awards Trials to DATATRAK
2. Eiger BioPharmaceuticals Announces Initiation of CLEAN-1 HCV Phase 1b Trial
3. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
4. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
5. CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders
6. DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD
7. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
8. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
9. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
10. Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma
11. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... DIEGO , April 17, 2015  Trovagene, ... diagnostics, announced today that clinical data presented at ... that its urine-based Precision Cancer Monitoring ℠ ... and monitoring of EGFR T790M mutations ... Detection of EGFR T790M Mutation in Urinary ...
(Date:4/17/2015)... DUBLIN , Apr. 17, 2015 Research and ... addition of the "Medical Oxygen Systems - Global ... This report analyzes the worldwide markets for Medical ... Oxygen Concentrators, Liquid Oxygen Systems, Oxygen Cylinders & Regulators, ... analytics for the US, Canada , ...
(Date:4/17/2015)... -- Today, the Pharmaceutical Research and Manufacturers of ... companies as "We Work For Health Champions" for ... service. Established in 2009, the We ... the biopharmaceutical industry to honor employees who have ... also shown an outstanding commitment to their communities ...
Breaking Medicine Technology:Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 2Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 3Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 4Medical Oxygen Systems - 2015 Global Strategic Business Report Featuring Leading Players, Caire, Invacare & Philips Respironics 2PhRMA Applauds 2015 We Work For Health Champion Award Winners 2PhRMA Applauds 2015 We Work For Health Champion Award Winners 3
... Water Street Healthcare Partners , a strategic private equity ... it has acquired MarketLab, Inc.  Water Street,s ... specialty healthcare distribution sector.  The acquisition expands Water Street,s ... life sciences, medical devices and services to 13. ...
... -- Dehaier Medical Systems Ltd. (NASDAQ: ... in the development, assembly, marketing and sale of medical ... that it was granted three new patents by State ... ("SIPO"). The patent awards were related to the design ...
Cached Medicine Technology:Water Street Healthcare Partners Acquires MarketLab, Inc. 2Water Street Healthcare Partners Acquires MarketLab, Inc. 3Dehaier Strengthens Intellectual Property Portfolio 2Dehaier Strengthens Intellectual Property Portfolio 3
(Date:4/18/2015)... Omaha, NE (PRWEB) April 18, 2015 ... leader in healthcare staffing, including physical therapy jobs, ... exhibitor at the South Carolina Physical Therapy Association ... at the Kroc Center in Greenville, SC. ... networking opportunities, and exhibits with products and services. ...
(Date:4/18/2015)... (PRWEB) April 18, 2015 PHOENIX, ARIZONA ... County, along with 11 other secure destruction professionals across ... Destruction Specialists (CSDS). He will now display “CSDS” as ... were offered before the National Association of Information Destruction ... and another Grapevine, Texas. Of the 20 people who ...
(Date:4/17/2015)... (PRWEB) April 18, 2015 Heritage Woods ... begin its Supportive Living Week Celebration on April 20 ... having a healthy mind, body and soul. , The ... McLeansboro, Illinois, serves older adults of all incomes, including ... their independence. , Supportive Living Week is observed every ...
(Date:4/17/2015)... Rosetta Radiology is proud to now offer ... of diagnostic imaging services. This solidifies them as a ... East Side of Manhattan. , The new imaging equipment ... of PET-CT, combined with Rosetta’s state of the art ... with patients through several stages of the cancer care ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 Riviera ... Dr. Kevin Sadati of the Gallery of Cosmetic ... County’s top beauty experts. The publication focused on ... facial stem cell fat grafting, eyelid surgery, laser resurfacing ... facial plastic surgery has resulted in thousands of ...
Breaking Medicine News(10 mins):Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the South Carolina Physical Therapy Association Annual Conference 2Health News:Heritage Woods of McLeansboro Affordable Assisted Living to Celebrate Supportive Living Week 2Health News:Heritage Woods of McLeansboro Affordable Assisted Living to Celebrate Supportive Living Week 3Health News:Orange County Facial Plastic Surgeon Featured in Premier Magazine Focused on Beauty 2Health News:Orange County Facial Plastic Surgeon Featured in Premier Magazine Focused on Beauty 3
... (Nasdaq: AMGN ) will present at the ... May 18, 2009 at the InterContinental, Boston, Mass., beginning ... Executive Officer Kevin Sharer will present. Live audio of ... can be accessed from Amgen,s Web site, www.amgen.com ...
... risk by 35%, study finds , , WEDNESDAY, May ... medications may ease the symptoms of bronchiolitis -- a ... research suggests this treatment may reduce the risk of ... wheezing sooner and get babies back to normal feeding ...
... Plan Yields Positive ResultsCLEVELAND, May 13 DATATRAK International, ... services company focused on global eClinical solutions for the ... the first quarter of 2009. Revenue for the first ... to $2,088,000 in the same period of 2008. Gross ...
... VIEW, Calif., May 13 MAP Pharmaceuticals, Inc. (Nasdaq: ... at the Deutsche Bank Securities 34th Annual Health ... (ET) in Boston, MA.A live webcast of the presentation will ... website at http://www.mappharma.com . A replay will also be ...
... from a study of managed-care cancer patients receiving chemotherapy ... the cumulative ESA cost with Epoetin alfa (EPO) was ... The analysis, published in the Spring issue of ... by Centocor Ortho Biotech Services, LLC. The retrospective ...
... a lawsuit against the U.S. Patent and Trademark Office and Myriad ... as BRCA1 and BRCA2, which are indicators for hereditary predisposition to ... ... May 13, 2009 -- The College of American Pathologists today joined ...
Cached Medicine News:Health News:Combo Treatment Eases Wheezing in Babies 2Health News:Combo Treatment Eases Wheezing in Babies 3Health News:DATATRAK International, Inc. Announces First Quarter Results for 2009 2Health News:DATATRAK International, Inc. Announces First Quarter Results for 2009 3Health News:DATATRAK International, Inc. Announces First Quarter Results for 2009 4Health News:DATATRAK International, Inc. Announces First Quarter Results for 2009 5Health News:DATATRAK International, Inc. Announces First Quarter Results for 2009 6Health News:Retrospective Analysis Finds Treatment of Cancer Chemotherapy Patients With Epoetin Alfa Associated With Lower Drug Cost Than Darbepoetin Alfa 2Health News:Retrospective Analysis Finds Treatment of Cancer Chemotherapy Patients With Epoetin Alfa Associated With Lower Drug Cost Than Darbepoetin Alfa 3Health News:Retrospective Analysis Finds Treatment of Cancer Chemotherapy Patients With Epoetin Alfa Associated With Lower Drug Cost Than Darbepoetin Alfa 4Health News:Retrospective Analysis Finds Treatment of Cancer Chemotherapy Patients With Epoetin Alfa Associated With Lower Drug Cost Than Darbepoetin Alfa 5Health News:Retrospective Analysis Finds Treatment of Cancer Chemotherapy Patients With Epoetin Alfa Associated With Lower Drug Cost Than Darbepoetin Alfa 6Health News:CAP Joins Landmark Lawsuit Challenging Legality of Myriad Genetics Gene Patents 2
... Choose from a complete ... and AC halogen light ... cool illumination. A solid-state ... intensity, and our exclusive ...
Inquire...
... inverted microscope technology that offers you much more ... in this category. You will be impressed by ... been designed to make lab work as easy ... efficiency of your workflow. Your advantage: more time ...
... represents the most advanced motorized inverted microscope ... and optical design provides 9 access ports ... to four ports can have simultaneous access ... motorized Z-axis drive, 6-position nosepiece and light ...
Medicine Products: